

Newer Antiepileptics May Worsen Osteoporosis

BY MARK BLOOM
Contributing Writer

BOSTON — Keep the risk of osteoporosis and osteopenia in mind when elderly patients are being treated even with the newer antiepileptic drugs, Georgia D. Montouris, M.D., said at a meeting on epilepsy in the elderly sponsored by Boston University.

While drug-to-drug interactions are less common with newer antiepileptic drugs (AEDs), there are no data suggesting they pose less of an osteoporosis risk than the earlier P450 enzyme-inducing versions do.

The diagnosis of new-onset seizures is made in an estimated 68,000 patients over age 60 every year in the United States, said Dr. Montouris, a neurologist at Boston University. All of these patients are at risk for osteoporosis.

"The fastest-growing population with new-onset seizures is over the age of 60, a large population that is in the prime years to develop osteoporosis," she said.

There is no evidence to support withdrawal of the enzyme-inducing antiepileptic medication to reverse the osteoporotic condition.

Dr. Montouris reported that she usually starts elderly patients with new-onset seizures on one of the newer AEDs that don't induce enzymes, to avoid drug-to-drug interactions and liver metabolism.

All of the older P450 enzyme-inducing drugs—carbamazepine, phenytoin, primidone, and phenobarbital—metabolize through the cytochrome P450 system. Phenobarbital, primidone, and phenytoin are most commonly associated with altered bone disease and decreased bone density, said Dr. Montouris. There are conflicting results for carbamazepine.

Lacking data on the effect of newer drugs on bone health, Dr. Montouris said she prefers not to switch older patients with epilepsy to newer AEDs when the older drugs have controlled their seizures for many years. In addition, there is no evidence to support withdrawal of the enzyme-inducing antiepileptic medication to reverse the osteoporotic condition.

The newer drugs, indicated as add-on agents for refractory seizures, include gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine hydrochloride, topiramate, and zonisamide. Oxcarbazepine is approved for monotherapy, lamotrigine is approved for conversion to monotherapy, and topiramate is under Food and Drug Administration evaluation for use in monotherapy. No information is available yet on the effect of these agents on bone health, she added.

"I feel it is more appropriate to keep them on a regimen that works and treat the bone health issues, than risk exacerbating the epilepsy and not improving bone health."

Seizures in this age group present most

often as confusion and mental status changes, putting the patients at risk for falls.

Dr. Montouris said she tries to correct a patient's vitamin D deficiency or insufficiency. She usually prescribes, as preventatives, supplementation with 200 IU of vitamin D twice a day, along with at least 500-600 mg (or more depending on age) of calcium twice per day. If signs of osteoporosis or osteopenia are present, she refers the patient to either an endocrinologist or a rheumatologist for assessment

and treatment. She prescribes a calcium-containing diet, weight-bearing exercise, and exposure to sunlight.

A vitamin D deficiency can lead to defects in calcium absorption and sometimes secondary hyperparathyroidism. "It's reported that carbamazepine and phenytoin can affect osteoblast formation," she said. "Phenytoin can actually reduce the intestinal calcium absorption as well." In epileptic patients taking AEDs, osteoporosis may occur as a result of the

medication and can lead to fractures of the hip and spine. "A tonic-clonic seizure is known to cause thoracic spine fractures," Dr. Montouris said.

She sends epileptic patients taking AEDs to be tested for baseline levels of 25-hydroxyvitamin D and parathyroid hormone and for a dual-photon absorptiometry scan.

The tests can be repeated 1-2 years later if normal or, if not, the patient should be treated or referred. ■



As an adjunct to diet

Make it to GOAL

Make it CRESTOR®

NOW MORE THAN 13 million PRESCRIPTIONS WORLDWIDE!

MORE PATIENTS
reached updated LDL-C goal with CRESTOR at a low 10-mg dose than atorvastatin 10 mg, simvastatin 20 mg, and pravastatin 40 mg*¹

PROVEN SAFETY
similar to other leading statins²
In preapproval clinical trials and postmarketing experience, CRESTOR has demonstrated a **safety profile similar to other leading statins**²⁻⁴

*In all risk categories combined, 68% of patients treated with CRESTOR 10 mg achieved updated LDL-C goal vs 50% with atorvastatin 10 mg, 56% with simvastatin 20 mg, and 50% with pravastatin 40 mg (P<.001). Comparisons shown are with the most commonly prescribed doses.⁵ LDL-C goal was <160 mg/dL, <130 mg/dL, <100 mg/dL, or <70 mg/dL, depending on individual risk factors.⁶

Adapted from the **STELLAR** trial, a 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with Type IIa/IIb dyslipidemia.⁷

Important Safety Information

- CRESTOR is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, non-HDL-C, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia
- CRESTOR is contraindicated in patients with active liver disease or with unexplained persistent elevations of serum transaminases, in women who are or may become pregnant, and in nursing mothers
- Adverse reactions were usually mild and transient; the most frequent adverse events thought to be related to CRESTOR were myalgia (3.3%), constipation (1.4%), asthenia (1.3%), abdominal pain (1.3%), and nausea (1.3%)^{3,8}
- The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined; long-term outcome studies are currently under way
- It is recommended that liver function tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (eg, semiannually) thereafter
- Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Discontinue drug if markedly elevated CK levels occur or myopathy is diagnosed or suspected

CRESTOR®
rosuvastatin calcium

Please see brief summary of full Prescribing Information on reverse side of this advertisement.